Introduction：Basic information about CAS 138148-68-2|N2'-Deacetyl-N2'-[3-(methyldithio)-1-oxopropyl]maytansine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | N2'-Deacetyl-N2'-[3-(methyldithio)-1-oxopropyl]maytansine |
|---|
| CAS Number | 138148-68-2 | Molecular Weight | 784.37900 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C36H50ClN3O10S2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | N2'-deacetyl-N2'-[3-(methyldithio)-1-oxopropyl]maytansine |
|---|
| Synonym | More Synonyms |
|---|
BiologicalActivity
| Description | DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is about 3-10-fold more potent than the parent drug Maytansine, with IC50s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines[1]. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Antibody-drug Conjugate >>ADC CytotoxinSignaling Pathways >>Cell Cycle/DNA Damage >>Microtubule/TubulinSignaling Pathways >>Cytoskeleton >>Microtubule/Tubulin |
|---|
| Target | Maytansinoids |
|---|
| References | [1]. Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(11):1860-1867. [2]. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107. |
|---|
Chemical & Physical Properties
| Molecular Formula | C36H50ClN3O10S2 |
|---|
| Molecular Weight | 784.37900 |
|---|
| Exact Mass | 783.26300 |
|---|
| PSA | 207.07000 |
|---|
| LogP | 5.30960 |
|---|
| InChIKey | ZLUUPZXOPGORNG-GDDHUJLSSA-N |
|---|
| SMILES | COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCSSC)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)C=CC=C(C)C2 |
|---|
Synonyms
| Maytansinoid DM1 |
| Mertansine |
